Table 3.

Baseline characteristics of in the 472 HCC patients

Variable	N	%	Mean ± SD
Clinical data
Age < = 65	328	69	60 ± 12
Male gender	419	89
ECOG
0	144	31
1	299	63
≥ 2	29	6
Cirrhosis (radiological)	278	59
Tumor morphology
Uninodular	122	26
Multinodular	143	30
Diffuse	207	44
Extrahepatic metastasis (nodal or distant)	108	23
Portal vein thrombosis	152	32
Hepatitis B surface antigen +	386	82
Hepatitis C antibody +	30	6
α-feto protein ≥200 mg/ml	250	53
ALBI score	472		−2.29 ± 1.33
Grade 1	155	32.8
Grade 2	265	56.2
Grade 3	52	11.0
MELD score	472		9.08 ± 4.05
Grade 1 (< 10)	319	67.6
Grade 2 (10–14)	109	21.4
Grade 3 (> 14)	52	11.0
Child-Pugh class
A	319	67.6
B	130	27.5
C	23	4.9
Albumin	472	100	37.4 ± 15.2
Bilirubin	472	100	32.8 ± 45.7
INR	472	100	1.15 ± 0.17
ALP	472	100	193.4 ± 155.8
ALT	472	100	77.3 ± 69.4
Albumin-to-ALP ratio	472	100	0.29 ± 0.22
ALP-to-platelet ratio	472	100	1.20 ± 1.19
Presence of ascites	122	25.8
Hemoglobin < 10 g/dL	27	6
White cell count > 10 × 109/L	64	14
Platelet count < 100 × 109/L	33	7
1st line Treatment
Surgical treatment	54	12
Local ablative therapies	29	6
Trans-arterial therapies	116	25
Systemic therapies	91	19
Best supportive care alone	182	38

EORTC European Organization for Research and Treatment of Cancer, ECOG Eastern Cooperative Oncology Group, ALBI Albumin-bilirubin, MELD Model for End-stage Liver Disease, INR international normalized ratio, ALP alkaline phosphatases, ALT alanine transaminase